I vaguely remember one of my rotations at the NIH back in the day. I sat in on meetings with high level individuals discussing therapeutics and implications of such. Knowledge of clinical data prior to is 100%. There’s a ton of logistics that come into play that need to be discussed before approval.
I’m not saying that’s what is happening here. I’m just saying it’s necessary in a situation like this